Ranolazine: a review of its use in chronic stable angina pectoris.

Drugs
M Asif A Siddiqui, Susan J Keam

Abstract

Ranolazine (Ranexa), a piperazine derivative, is a new antianginal agent approved for the treatment of chronic stable angina pectoris for use as combination therapy when angina is not adequately controlled with other antianginal agents. While the exact mechanism of action of ranolazine is not known, its antianginal and anti-ischaemic effects do not appear to depend upon changes in blood pressure or heart rate. An extended-release (ER) oral formulation of ranolazine has been developed to facilitate twice-daily administration whilst maintaining therapeutically effective plasma concentrations. In patients with chronic stable angina, ranolazine ER monotherapy was shown to improve exercise duration at trough plasma drug concentration in a dose-dependent manner compared with placebo. The drug was effective as adjunctive therapy in patients with chronic stable angina whose condition was not controlled adequately with conventional antianginal therapy. In randomised clinical trials, ranolazine ER was well tolerated, with no overt effects on cardiovascular haemodynamics or conduction, apart from a modest increase in corrected QT (QTc) interval (but no torsades de pointes). Importantly, the efficacy and tolerability of ranolazine ER were ...Continue Reading

References

Dec 1, 1994·Journal of Cardiovascular Pharmacology·S C BlackB R Lucchesi
Aug 1, 1994·Cardiovascular Research·M R GralinskiB R Lucchesi
Feb 1, 1996·Journal of Molecular and Cellular Cardiology·B ClarkeJ G McCormack
May 1, 1996·British Journal of Pharmacology·T J Allen, R A Chapman
Mar 3, 1998·International Journal of Cardiology·A D Staniforth
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Apr 1, 1996·Journal of Cardiovascular Pharmacology and Therapeutics·M R GralinskiB R Lucchesi
Oct 17, 2001·Annals of Internal Medicine·S D FihnUNKNOWN American College of Physicians-American Society of Internal Medicine
Aug 24, 2002·Circulation Research·Margaret P ChandlerHani N Sabbah
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Bernard R ChaitmanUNKNOWN Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators
Apr 20, 2004·Journal of the American College of Cardiology·Bernard R ChaitmanUNKNOWN MARISA Investigators
Jan 27, 2005·The American Journal of Cardiology·Michel F RousseauAndrew A Wolff
Jun 14, 2005·Journal of Clinical Pharmacology·Hisham Abdallah, Markus Jerling
Sep 13, 2005·Clinical Pharmacology and Therapeutics·Markus Jerling, Hisham Abdallah

❮ Previous
Next ❯

Citations

Nov 18, 2010·Herzschrittmachertherapie & Elektrophysiologie·U Ravens, T Christ
Jan 16, 2015·American Journal of Therapeutics·Mukesh Singh, Rohit Arora
Jul 27, 2010·Cardiovascular Drugs and Therapy·Danny Dvir, Alexander Battler
Mar 8, 2016·PloS One·Martin AldasoroSoraya L Valles
Oct 3, 2008·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Amish N Raval
Feb 2, 2021·Clinical Therapeutics·Hyounggyoon YooSeungHwan Lee
Apr 8, 2021·European Heart Journal·Bernard J GershThomas F Lüscher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.